Posaconazole medicine study in transplant patients with mouth sores
Treatments studied
Part of Digestive system, Mouth & dental clinical trials.
This study looks at how posaconazole (an antifungal medicine) moves through the body in people who recently had an allogeneic stem cell transplant and have mouth sores (mucositis). It may help clinicians choose the safest and most effective dosing for preventing serious fungal infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are receiving or have received an allogeneic stem cell transplant (using donor cells)
- You are taking posaconazole to prevent fungal infections
- You are using posaconazole by mouth as either tablets (300 mg once daily) or oral suspension (200 mg three times daily)
- You are age 18 or older
- You do not have stomach paralysis (gastroparesis)
- You do not vomit or have diarrhea within 2 hours after taking posaconazole
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests an oral “fecal microbiotherapy” treatment given before and around an allogeneic (donor) stem-cell transplant to help prevent transplant-related complications. It may help by improving gut and immune function during the high-risk transplant period.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
This trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in people who are at high risk after a stem cell transplant. If you qualify, you would take posaconazole during your recovery.
This trial tests if giving the antifungal drug posaconazole as a tablet can prevent serious fungal infections in people who have had a stem cell transplant and develop gut graft-versus-host disease (GVHD), which is a complication where donor cells attack the digestive tract. It may help protect patients who need strong immune-suppressing treatment for GVHD.
This study looks at how much posaconazole stays in your body while you receive it to prevent fungal infections during chemotherapy or after a stem cell transplant. Your care team will use standard posaconazole treatment and may take extra blood samples to understand its levels.
This trial tests whether posaconazole, given through a vein or by mouth, can treat invasive fungal infections in children under 2 years old. It may help improve outcomes for infants with hard-to-treat fungal disease.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.